A current effort to directly correct the dystrophin deficiency in DMD is being piloted in the mdx mouse using CRISPR/Cas9 to edit the genetic defect as a therapeutic strategy (15, 27). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.